IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

BACKGROUND: The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1 therapy for autosomal dominant cerebellar ataxia (ADCA) patients. RESULTS: A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7 compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanz-Gallego, Irene, Rodriguez-de-Rivera, Francisco J, Pulido, Irene, Torres-Aleman, Ignacio, Arpa, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552149/
https://www.ncbi.nlm.nih.gov/pubmed/26331037
http://dx.doi.org/10.1186/s40673-014-0013-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552149/
https://www.ncbi.nlm.nih.gov/pubmed/26331037
http://dx.doi.org/10.1186/s40673-014-0013-8

Ejemplares similares